European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently-diagnosed type 1 diabetes

Clinical and preclinical studies, together with supportive mechanistic data showing that Tregs are activated by much lower IL2 concentration than effector T cells (Teffs), provide a strong rationale for studying efficacy of low dose IL2 to stop the autoimmune destruction of insulin-secreting beta cells in patient with recently diagnosed with T1D.

For more information on DIABIL-2 project, please click here​

For more information on the clinical trial, please click here